Iqvia Holdings Inc (IQV) Receives Average Rating of “Buy” from Brokerages

Share on StockTwits

Iqvia Holdings Inc (NYSE:IQV) has received an average rating of “Buy” from the eighteen brokerages that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $139.29.

IQV has been the subject of a number of recent research reports. Goldman Sachs Group upgraded Iqvia from a “buy” rating to a “conviction-buy” rating in a report on Friday, January 11th. Jefferies Financial Group upgraded Iqvia from a “hold” rating to a “buy” rating and boosted their price objective for the company from $136.00 to $150.00 in a report on Friday, January 18th. Royal Bank of Canada boosted their price objective on Iqvia to $137.00 and gave the company an “outperform” rating in a report on Tuesday, October 23rd. Barclays boosted their price objective on Iqvia from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, October 23rd. Finally, Piper Jaffray Companies boosted their price objective on Iqvia to $131.00 and gave the company a “neutral” rating in a report on Tuesday, October 23rd.

In other news, major shareholder Canada Pension Plan Investment sold 3,164,388 shares of the business’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $123.72, for a total value of $391,498,083.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronald A. Rittenmeyer sold 3,840 shares of the business’s stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $130.00, for a total value of $499,200.00. The disclosure for this sale can be found here. Insiders sold a total of 6,751,273 shares of company stock valued at $835,335,596 over the last quarter. Company insiders own 6.00% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Argent Trust Co raised its position in shares of Iqvia by 0.5% in the 4th quarter. Argent Trust Co now owns 15,406 shares of the medical research company’s stock worth $1,790,000 after acquiring an additional 80 shares in the last quarter. Utah Retirement Systems raised its position in shares of Iqvia by 0.3% in the 4th quarter. Utah Retirement Systems now owns 30,360 shares of the medical research company’s stock worth $3,527,000 after acquiring an additional 100 shares in the last quarter. Creative Planning raised its position in shares of Iqvia by 4.2% in the 4th quarter. Creative Planning now owns 2,925 shares of the medical research company’s stock worth $340,000 after acquiring an additional 118 shares in the last quarter. Ffcm LLC raised its position in shares of Iqvia by 10.8% in the 4th quarter. Ffcm LLC now owns 1,544 shares of the medical research company’s stock worth $179,000 after acquiring an additional 150 shares in the last quarter. Finally, HL Financial Services LLC increased its position in Iqvia by 4.8% during the 4th quarter. HL Financial Services LLC now owns 3,654 shares of the medical research company’s stock valued at $424,000 after buying an additional 167 shares in the last quarter. 93.62% of the stock is owned by hedge funds and other institutional investors.

Shares of Iqvia stock traded up $2.04 on Tuesday, reaching $131.14. The company had a trading volume of 48,041 shares, compared to its average volume of 1,153,382. The stock has a market cap of $25.77 billion, a price-to-earnings ratio of 30.05, a price-to-earnings-growth ratio of 1.59 and a beta of 0.88. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.09 and a current ratio of 1.09. Iqvia has a 1 year low of $91.57 and a 1 year high of $139.65.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Read More: Cost of Capital Explained

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Critical Review: COBHAM PLC/ADR  & ORIENTAL LD CO/ADR
Critical Review: COBHAM PLC/ADR & ORIENTAL LD CO/ADR
Haverty Furniture Companies  Hits New 12-Month High After Better-Than-Expected Earnings
Haverty Furniture Companies Hits New 12-Month High After Better-Than-Expected Earnings
Summit Materials  Shares Up 7.4% Following Insider Buying Activity
Summit Materials Shares Up 7.4% Following Insider Buying Activity
Ascential’s  “Buy” Rating Reaffirmed at Shore Capital
Ascential’s “Buy” Rating Reaffirmed at Shore Capital
Centrica  Downgraded to Hold at Berenberg Bank
Centrica Downgraded to Hold at Berenberg Bank
Peel Hunt Boosts Future  Price Target to GBX 660
Peel Hunt Boosts Future Price Target to GBX 660


Leave a Reply

© 2006-2019 Ticker Report